Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: Post hoc analysis of a randomized controlled 4.3 year trial

Journal of Diabetes and its Complications

Volumn 32, Issue 2, 2018, Pages 171-178

  Out, Mattijs ^a,b   Kooy, Adriaan ^a,b,c   Lehert, Philippe ^d   Schalkwijk, Casper A ^e   Stehouwer, Coen D A ^e  

^a Care Group Treant   (Netherlands)

^b Bethesda Diabetes Research Center   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Facultes Universitaires Catholiques de Mons   (Belgium)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

B12; Complication; Metformin; Methylmalonic acid; Neuropathy; Type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM; CYANOCOBALAMIN; HEMOGLOBIN A1C; HOMOCYSTEINE; INSULIN; METFORMIN; METHYLMALONIC ACID; PLACEBO; PROTON PUMP INHIBITOR; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFECT; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VITAMIN BLOOD LEVEL; BLOOD; COMPLICATION; CYANOCOBALAMIN DEFICIENCY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; METFORMIN; METHYLMALONIC ACID; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TIME FACTORS; VITAMIN B 12; VITAMIN B 12 DEFICIENCY;

EID: 85034655371     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2017.11.001     Document Type: Article

References (40)

1. American Diabetes Association, 8. Pharmacologic approaches to glycemic treatment. Diabetes Care 40 (2017), S64–74.
2. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352, 1998, 854–865.
3. Kooy, A., de Jager, J., Lehert, P., et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 169 (2009), 616–625.
4. Pernicova, I., Korbonits, M., Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10 (2014), 143–156.
5. Aroda, V.R., Edelstein, S.L., Goldberg, R.B., et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab 101 (2016), 1754–1761.
6. Chapman, L.E., Darling, A.L., Brown, J.E., Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes: a systematic review and meta-analysis. Diabete Metab 42 (2016), 316–327.
7. Zdilla, M.J., Metformin with either histamine H2-receptor antagonists or proton pump inhibitors: a polypharmacy recipe for neuropathy via vitamin B12 depletion. Clin Diabetes 33 (2015), 90–95.
8. Wulffele, M.G., Kooy, A., Lehert, P., et al. Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med 254 (2003), 455–463.
9. de Jager, J., Kooy, A., Lehert, P., et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ, 340, 2010, c2181.
10. Saperstein, D.S., Barohn, R.J., Peripheral neuropathy due to cobalamin deficiency. Curr Treat Options Neurol 4 (2002), 197–201.
11. Bell, D.S., Nondiabetic neuropathy in a patient with diabetes. Endocr Pract 1 (1995), 393–394.
12. Wile, D.J., Toth, C., Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care 33 (2010), 156–161.
13. Singh, A.K., Kumar, A., Karmakar, D., Jha, R.K., Association of B12 deficiency and clinical neuropathy with metformin use in type 2 diabetes patients. J Postgrad Med 59 (2013), 253–257.
14. Chen, S., Lansdown, J.A., Moat, S.J., et al. An observational study of the effect of metformin on B12 status and peripheral neuropathy. Br J Diab Vasc Dis 12 (2012), 189–193.
15. de Groot-Kamphuis, D.M., van Dijk, P.R., Groenier, K.H., Houweling, S.T., Bilo, H.J., Kleefstra, N., Vitamin B12 deficiency and the lack of its consequences in type 2 diabetes patients using metformin. Neth J Med 71 (2013), 386–390.
16. Hansen, C.S., Jensen, J.S., Ridderstrale, M., Vistisen, D., Jorgensen, M.E., Fleischer, J., Vitamin B12 deficiency is associated with cardiovascular autonomic neuropathy in patients with type 2 diabetes. J Diabetes Complicat 31 (2017), 202–208.
17. Pop-Busui, R., Lu, J., Brooks, M.M., et al. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) cohort. Diabetes Care 36 (2013), 3208–3215.
18. Stabler, S.P., Clinical practice. Vitamin B12 deficiency. N Engl J Med 368 (2013), 149–160.
19. Carmel, R., Biomarkers of cobalamin (vitamin B-12) status in the epidemiologic setting: a critical overview of context, applications, and performance characteristics of cobalamin, methylmalonic acid, and holotranscobalamin II. Am J Clin Nutr 94 (2011), 348S–358S.
20. Wulffele, M.G., Kooy, A., Lehert, P., et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 25 (2002), 2133–2140.
21. Valk, G.D., Nauta, J.J., Strijers, R.L., Bertelsmann, F.W., Clinical examination versus neurophysiological examination in the diagnosis of diabetic polyneuropathy. Diabet Med 9 (1992), 716–721.
22. Levey, A.S., Stevens, L.A., Schmid, C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
23. Bauman, W.A., Shaw, S., Jayatilleke, E., Spungen, A.M., Herbert, V., Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 23 (2000), 1227–1231.
24. Abraham, N.S., Proton pump inhibitors: potential adverse effects. Curr Opin Gastroenterol 28 (2012), 615–620.
25. Berchtold, P., Bolli, P., Arbenz, U., Keiser, G., Disturbance of intestinal absorption following metformin therapy (observations on the mode of action of biguanides). Diabetologia 5 (1969), 405–412.
26. Bell, D.S., Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy. South Med J 103 (2010), 265–267.
27. Tung, M.L., Tan, L.K., Long term use of metformin leading to vitamin B 12 deficiency. Diabetes Res Clin Pract 104 (2014), e75–e76.
28. Callaghan, T.S., Hadden, D.R., Tomkin, G.H., Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment. Br Med J 280 (1980), 1214–1215.
29. Leung, S., Mattman, A., Snyder, F., Kassam, R., Meneilly, G., Nexo, E., Metformin induces reductions in plasma cobalamin and haptocorrin bound cobalamin levels in elderly diabetic patients. Clin Biochem 43 (2010), 759–760.
30. Greibe, E., Trolle, B., Bor, M.V., Lauszus, F.F., Nexo, E., Metformin lowers serum cobalamin without changing other markers of cobalamin status: a study on women with polycystic ovary syndrome. Forum Nutr 5 (2013), 2475–2482.
31. Solomon, L.R., Diabetes as a cause of clinically significant functional cobalamin deficiency. Diabetes Care 34 (2011), 1077–1080.
32. England, J.D., Gronseth, G.S., Franklin, G., et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 72 (2009), 185–192.
33. McCracken, C., Hudson, P., Ellis, R., McCaddon, A., Medical Research Council Cognitive Function and Ageing Study. Methylmalonic acid and cognitive function in the Medical Research Council Cognitive Function and Ageing Study. Am J Clin Nutr 84 (2006), 1406–1411.
34. Carlsen, S.M., Folling, I., Grill, V., Bjerve, K.S., Schneede, J., Refsum, H., Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease. Scand J Clin Lab Invest 57 (1997), 521–527.
35. Obeid, R., Jung, J., Falk, J., et al. Serum vitamin B12 not reflecting vitamin B12 status in patients with type 2 diabetes. Biochimie 95 (2013), 1056–1061.
36. Carmel, R., Diagnosis and management of clinical and subclinical cobalamin deficiencies: why controversies persist in the age of sensitive metabolic testing. Biochimie 95 (2013), 1047–1055.
37. Fonseca, V.A., Lavery, L.A., Thethi, T.K., et al. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. Am J Med 126 (2013), 141–149.
38. Ismail-Beigi, F., Craven, T., Banerji, M.A., et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376 (2010), 419–430.
39. El-Mir, M.Y., Detaille, D., R-Villanueva, G., et al. Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci 34 (2008), 77–87.
40. Dyck, P.J., Overland, C.J., Low, P.A., et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve 42 (2010), 157–164.